Beam Therapeutics Inc.
BEAM- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001745999
In the last 90 days, Beam Therapeutics Inc. insiders filed 0 open-market purchases and 1 sale; 277 institutions reported holding it in 13F filings for Q2 2026, worth $3.75B in total; superinvestors ARK Invest and Duquesne Family Office hold it.
Q1 2023 vs. Q4 2022
How the institutions holding Beam Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 209 | 1 | 207 | −1 |
| Shares | 55.8M | 15 | 60.4M | +4.55M (+8.1%) |
| Value | $2.18B | $587 | $1.85B | −$335.1M (−15.3%) |
1 institution that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (29)
Institutions that held Beam Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (30)
Institutions that held Beam Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
Not filed for Q1 2023 yet (1)
Institutions that held Beam Therapeutics Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Trustcore Financial Services, LLC | 15 | $587 |